[{"id":"5cfe778d-fe5e-47ad-9d92-bcdc82f98727","acronym":"SORENTO","url":"https://clinicaltrials.gov/study/NCT05050942","created_at":"2021-09-21T11:53:31.080Z","updated_at":"2024-07-02T16:35:22.027Z","phase":"Phase 3","brief_title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","source_id_and_acronym":"NCT05050942 - SORENTO","lead_sponsor":"Camurus AB","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous • Oclaiz (octreotide subcutaneous depot) • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 332","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-26"},{"id":"dcf070b8-c1c9-42c7-86fb-590929bf423e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02299089","created_at":"2021-01-18T10:50:48.870Z","updated_at":"2025-02-25T15:42:05.057Z","phase":"Phase 2","brief_title":"Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)","source_id_and_acronym":"NCT02299089","lead_sponsor":"Camurus AB","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Oclaiz (octreotide subcutaneous depot) • octreotide acetate • octreotide acetate solution for injection"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2017-12-15"}]